Imagenomix
Imagenomix Corp is an AI-driven cancer diagnostics company whose IGX Predict platform predicts cancer-causing genetic mutations from standard H&E pathology slides in minutes, serving pathology practices, pharmaceutical companies for clinical trial optimization, and biotechnology firms for drug discovery support.
- Company typePrivate
- Founded2024
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Imagenomix does
Imagenomix Corp is a privately held AI-driven cancer diagnostics company founded in 2024 as a spin-off from NYU Langone Health. The company develops the IGX Predict AI platform, which uses proprietary computational models to predict cancer-causing genetic mutations from standard Hematoxylin and Eosin (H&E) stained pathology slides within minutes, rather than the weeks required by traditional molecular testing. The technology addresses the problem that 26% of cancer samples are insufficient for traditional testing and claims applicability to 100% of confirmed cancer cases, with positioning that only 20% of US patients and 2% globally currently receive molecular testing.
The product portfolio spans mutation prediction and sample adequacy analysis, whole slide image analysis, custom AI model development for biotech and pharma clients, predictive modeling, multi-omics data analysis, and consulting and telepathology services. An IT Reporting System is under development to deliver comprehensive diagnostic insights to clients. The underlying technology combines computer vision on pathology images with predictive analytics and multimodal integration of multi-omics and clinical data, protected by multiple patent-pending applications credited to co-founder Aris Tsirigos.
Imagenomix operates a B2B sales-led go-to-market targeting three primary customer segments: pathology practices (hospitals and independent laboratories seeking faster, more affordable molecular cancer testing), pharmaceutical companies (clinical trial patient stratification and biomarker identification), and biotechnology firms (drug discovery support and custom AI models). Revenue is generated through subscription-based diagnostic services to pathology practices and professional services fees from pharma/biotech partnerships and custom AI model development, with quote-based enterprise contracts and no publicly disclosed pricing. Distribution is direct enterprise sales, supported by strategic partnerships with Amazon Web Services (cloud infrastructure and Health Equity Initiative, June 2024) and Alterome Therapeutics (clinical trial collaboration, January 2025). The company is headquartered in New York City, reports 1-10 employees, and has disclosed one funding round of $3.2 million led by Modi Ventures.
Imagenomix firmographics
Firmographics- Name
- Imagenomix
- Legal name
- Imagenomix Corp
- Website
- https://imagenomix.ai
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Imagenomix Corp is an AI-driven cancer diagnostics company whose IGX Predict platform predicts cancer-causing genetic mutations from standard H&E pathology slides in minutes, serving pathology practices, pharmaceutical companies for clinical trial optimization, and biotechnology firms for drug discovery support.
- Ownership category
- akta.pro rank
Imagenomix industry classification
Industry- Product category
- AI Cancer Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)SaMD – Imaging & Signal Analysis (AI/ML)Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
Keywords
Where Imagenomix is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Imagenomix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Diagnostic Services: AI-based analysis of H&E slides and fresh tissue for detection of cancer-causing mutations provided to pathology practices and healthcare organizations.
- Pharmaceutical Partnership Services: Collaboration with pharmaceutical companies to optimize clinical trials through AI-powered analytics for patient stratification and biomarker identification.
- Custom AI Model Development: Development of custom AI models tailored to unique client requirements such as mutation detection or drug response prediction for biotech and pharmaceutical clients.
- Consulting and Telepathology Services: Expert pathologist, data scientist, and AI engineer consulting services to help healthcare organizations integrate AI into pathology workflows.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Imagenomix product offering
Product offeringCore offering
Imagenomix sells AI-driven cancer diagnostics through its IGX Predict platform, which computationally predicts cancer-causing driver mutations from standard H&E stained pathology slides in minutes. The company also offers custom AI model development, predictive modeling, image analysis, data analysis, and consulting/telepathology services to pharmaceutical, biotechnology, and pathology customers.
Product overview
Imagenomix offers a unified AI-driven diagnostic platform centered on the IGX Predict system, which provides cancer mutation prediction by analyzing standard H&E pathology slides in minutes rather than weeks. The platform architecture includes core diagnostic services (mutation prediction, image analysis, predictive modeling, data analysis) along with custom AI model development capabilities for pharmaceutical and biotech clients. The company also provides consulting and telepathology services to help healthcare organizations integrate AI into pathology workflows. An IT Reporting System is under development to deliver comprehensive diagnostic insights to clients.
Differentiator
Problem solved
Functional benefit
Brands
- IGX Predict: AI platform that predicts driver mutations for cancer treatment or clinical trials within minutes using computational rather than wet-lab-based techniques.
- IGX Predict AI Pharma
Products and services
- IGX Predict AI platform that predicts cancer-causing driver mutations from standard H&E pathology slides within minutes for cancer treatment decisions and clinical trial enrollment, used by pharmaceutical companies and pathology practices.
- Mutation Prediction and Sample Adequacy Analysis Service that predicts targetable mutations and fusions, maps spatial distribution of mutations from pathology tissue, and assesses tissue adequacy for downstream NGS testing, offered to pathology practices and healthcare organizations.
- Custom AI Models Bespoke AI model development service for biotech and pharmaceutical clients requiring tailored mutation detection or drug response prediction capabilities.
- Image Analysis AI-powered analysis of whole slide pathology images to identify and classify cancer cells, tumor margins, and disease markers for pathology practices and pharma clients.
- Data Analysis Analytical service processing large datasets from clinical trials, biobanks, and electronic health records to identify biomarkers, genetic variants, and drug targets for biotech and pharma clients.
- Predictive Modeling Predictive modeling service that generates disease prognosis, treatment response, and drug efficacy predictions from molecular data and patient characteristics for healthcare and pharma clients.
- Consulting and Telepathology Consulting and telepathology services delivered by expert pathologists, data scientists, and AI engineers to help healthcare organizations and biotech companies integrate AI into pathology workflows.
Quantifiable outcome
- Diagnostic results delivered in minutes vs weeks
- +4 more outcomes
Companies that use Imagenomix
Customer profileSegments3 records
Ideal customer profiles3 records
Imagenomix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Imagenomix partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Alterome Therapeutics Inc.flagshipGroundbreaking partnership to leverage Imagenomix's cutting-edge AI technologies to optimize clinical trial efficiency, improve patient stratification, and accelerate the development of Alterome's targeted cancer therapies. The Imagenomix Predict AI platform will streamline clinical trial timelines through advanced analytics for critical biomarker identification and targeted patient selection.
- Amazon Web Services (AWS)coreSelected for AWS Health Equity Initiative, a $60 million three-year commitment supporting organizations developing solutions for health equity. Imagenomix will receive computing credits and technical expertise from AWS to further validate the IGX Predict AI Assay for launch with pharma partners to develop cancer mutational cancer screening for targeted therapies globally.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Imagenomix competitors and assessment
Company assessmentDirect peers
- Owkin: Owkin uses AI on patient data including pathology and omics for drug discovery and clinical trial optimization, with pharma collaborations. Comparable in combining pathology AI with pharma/biotech GTM motion.
- PathAI: PathAI develops AI-powered pathology diagnostics for cancer and other diseases, directly competing with Imagenomix in AI-driven mutation detection from H&E slides and serving both pathology practices and pharma/biotech for clinical trial applications.
- nference: nference applies AI to biomedical data including pathology, omics, and clinical records to support pharma R&D and clinical development. Comparable in AI-driven biomedical analytics targeting pharma/biotech customers.
- Ibex Medical Analytics: Ibex deploys AI for cancer diagnostics in pathology workflows, offering H&E-based detection and decision support tools. Directly comparable as an AI-first pathology company serving clinical labs and healthcare providers.
- Paige.AI: Paige builds AI applications for pathology, including cancer detection and biomarker prediction from H&E slides, with pharma partnerships for clinical trials. Closely comparable in technology approach and target customer segments.
- ArteraAI: ArteraAI develops AI-based multimodal prognostic and predictive biomarkers in oncology, combining pathology images with clinical data. Comparable in using AI on pathology images to predict outcomes and inform treatment decisions in cancer.
Broad incumbents
- Tempus: Tempus is a leading precision medicine company combining genomic sequencing, AI, and clinical data for oncology. Broadly overlaps with Imagenomix on AI-driven molecular profiling and pharma clinical trial services, but operates at much larger scale with NGS infrastructure.
- Foundation Medicine: Foundation Medicine (Roche) provides comprehensive genomic profiling assays for oncology, serving pharma for clinical trial enrollment and clinical practice. Overlaps in molecular cancer diagnostics and pharma partnerships, but uses NGS rather than H&E inference.
Emerging players
- Proscia: Proscia provides AI-enabled digital pathology software for cancer diagnosis and research, serving pharma and clinical labs. Comparable as a digital pathology platform company with AI analytics for pharma/biotech customers.
- Stratipath: Stratipath uses AI on H&E slides for breast cancer risk stratification and prognostic biomarker prediction. Direct technological overlap as an AI pathology company focused on H&E-based biomarker inference.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Imagenomix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imagenomix leadership team
Management profileNumber of profiles
Profiles6 records
Imagenomix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imagenomix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imagenomix
What does Imagenomix do?
Imagenomix sells AI-driven cancer diagnostics through its IGX Predict platform, which computationally predicts cancer-causing driver mutations from standard H&E stained pathology slides in minutes. The company also offers custom AI model development, predictive modeling, image analysis, data analysis, and consulting/telepathology services to pharmaceutical, biotechnology, and pathology customers.
Is Imagenomix a public or private company?
Imagenomix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Imagenomix founded?
Imagenomix was founded in 2024. It employs 1 to 10 people.
Where is Imagenomix based?
Imagenomix is headquartered in New York, United States, in the North America region.
How does Imagenomix make money?
Four revenue lines are on record. Diagnostic Services are the primary driver. The others are pharmaceutical Partnership Services, custom AI Model Development and consulting and Telepathology Services.
Who are Imagenomix's main competitors?
Direct peers on record are Owkin, PathAI, nference, Ibex Medical Analytics, Paige.AI and ArteraAI. Broad incumbents are Tempus and Foundation Medicine. Emerging players are Proscia and Stratipath.
Does Imagenomix have an API?
No public API is recorded for Imagenomix.
What industry is Imagenomix in?
Imagenomix's product category is AI Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 62151 and its SIC code is 3826.